HC Wainwright Issues Pessimistic Forecast for Cognition Therapeutics (NASDAQ:CGTX) Stock Price

Cognition Therapeutics (NASDAQ:CGTX) had its price objective reduced by equities researchers at HC Wainwright from $6.00 to $5.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright also issued estimates for Cognition Therapeutics’ Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS and Q4 2026 earnings at ($0.07) EPS.

A number of other equities analysts have also commented on CGTX. Chardan Capital cut their price target on shares of Cognition Therapeutics from $11.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, March 21st. Brookline Capital Management raised Cognition Therapeutics to a “strong-buy” rating in a report on Monday, January 27th. Finally, B. Riley upgraded Cognition Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the company from $1.00 to $1.50 in a research report on Thursday, December 19th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Cognition Therapeutics has a consensus rating of “Buy” and a consensus target price of $7.50.

Cognition Therapeutics Trading Down 6.2 %

Shares of CGTX stock opened at $0.46 on Monday. The firm has a market capitalization of $19.08 million, a price-to-earnings ratio of -0.47 and a beta of 1.03. The business’s 50-day moving average price is $0.57 and its 200-day moving average price is $0.55. Cognition Therapeutics has a 12 month low of $0.34 and a 12 month high of $2.95.

Cognition Therapeutics (NASDAQ:CGTX) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). During the same quarter last year, the company posted ($0.27) EPS. On average, sell-side analysts predict that Cognition Therapeutics will post -0.8 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cognition Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BIOS Capital Management LP bought a new position in shares of Cognition Therapeutics in the 4th quarter worth about $4,208,000. Voss Capital LP acquired a new stake in Cognition Therapeutics during the fourth quarter worth approximately $351,000. Sigma Planning Corp increased its holdings in Cognition Therapeutics by 211.6% in the fourth quarter. Sigma Planning Corp now owns 614,490 shares of the company’s stock worth $431,000 after purchasing an additional 417,300 shares in the last quarter. Virtu Financial LLC acquired a new position in Cognition Therapeutics in the third quarter valued at approximately $27,000. Finally, Two Sigma Investments LP lifted its stake in Cognition Therapeutics by 372.2% in the fourth quarter. Two Sigma Investments LP now owns 53,691 shares of the company’s stock valued at $38,000 after buying an additional 42,321 shares during the period. Institutional investors and hedge funds own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.